GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Preferred Dividends

GlycoNex (ROCO:4168) Preferred Dividends : NT$0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. GlycoNex's preferred dividends for the three months ended in Mar. 2025 was NT$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2025 was NT$0.00 Mil.


GlycoNex Preferred Dividends Historical Data

The historical data trend for GlycoNex's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Preferred Dividends Chart

GlycoNex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoNex Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GlycoNex Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


GlycoNex  (ROCO:4168) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlycoNex Business Description

Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The Company also provides antibody research services to its academic and industrial clients. The other services provided by the firm include functional evaluation and antibody engineering. The company has two segments which are antibody new drugs and exclusive investment. It earns the majority of its revenue from the antibody new drugs segment.

GlycoNex Headlines

No Headlines